Chemotherapy News and Research

Latest Chemotherapy News and Research

OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company’s potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).

4 Sep 2009

Oncotype DX multigene expression test for breast cancer patients

In an effort to provide breast cancer patients with prompt, critical information about treatment options for use at their first visit with the medical oncologist, a number of leading U.S. surgeons request Genomic Health's Oncotype DX molecular test at the time of surgery or biopsy.

4 Sep 2009

NCI renews SPORE grant for the diagnosis and treatment of ovarian cancer

National Cancer Institute (NCI) has renewed a $11.5 million Specialized Program of Research Excellence (SPORE) grant in prevention, diagnosis and treatment of ovarian cancer, which supports multidisciplinary research at Fox Chase Cancer Center and the University of Pennsylvania. First approved in 1999, this marks the third five-year term for the Fox Chase-Penn Ovarian SPORE.

4 Sep 2009

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

Endo Pharmaceuticals (Nasdaq: ENDP) today announced the availability of VALSTAR(TM) (valrubicin) for the treatment of a distinct form of bladder cancer. VALSTAR is the only FDA-approved intravesical therapy for patients with Bacille Calmette-Guerin (BCG)-refractory carcinoma in situ (CIS) of the urinary bladder for whom immediate removal of the bladder would be associated with unacceptable medical risks.

3 Sep 2009

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM).

3 Sep 2009

First-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the first quarter of fiscal year (FY) 2010 ended July 31, 2009. Total revenues for the first quarter of FY 2010 increased 345% to $6,750,000, compared to $1,517,000 for the comparable prior year quarter. This increase was primarily generated from increased government contract revenue and from increased sales by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.

3 Sep 2009

Delcath Systems begins operations facility in Queensbury, New York

Delcath Systems, Inc. (Nasdaq: DCTH), a Manhattan headquartered medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that it has signed a three-year lease with the option to buy on a 10,000 square foot facility in Queensbury, New York in which it plans to locate manufacturing of its Percutaneous Hepatic Perfusion (PHP(TM)) System.

3 Sep 2009

IsoFlow Infusion catheter allows physicians to increase drug concentrations at targeted sites

Vascular Designs, a medical device company, today announced that its IsoFlow(TM) infusion catheter has secured 510(k) marketing clearance by the U.S. Food and Drug Administration (FDA) for the direct delivery of medications into highly targeted areas. An important application of IsoFlow may be in the treatment of cancer.

3 Sep 2009

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

A key compound resupplies bone marrow with fast-acting stem cells that can more quickly rekindle blood cell production, according to a study published online today in the journal Blood. While the study was in mice, in the study authors say it has the potential to increase survival among patients with life-threatening blood cell shortages.

3 Sep 2009

GDC-0449 inhibits the Hedgehog signaling pathway

The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage.

3 Sep 2009

Research reveals that 21% of death claims are rejected by California's largest private insurers

More than one of every five requests for medical claims for insured patients, even when recommended by a patient's physician, are rejected by California's largest private insurers, amounting to very real death panels in practice daily in the nation's biggest state, according to data released today by the California Nurses Association/National Nurses Organizing Committee.

3 Sep 2009

Yale University awarded $36 million ARRA funds for over 100 research projects

Faculty at Yale University have been awarded over 100 research grants totaling $36 million since February 2009, when the federal stimulus package was signed into law. Known as the American Recovery and Revitalization Act of 2009 (ARRA), the law aims to reinvigorate the economy and lay the foundation for long-term economic recovery by increasing investments in infrastructure, education, the environment and scientific research.

3 Sep 2009

Avastin increases survival rates in recurrent glioblastoma affected patients

The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred.

3 Sep 2009

New target for cancer cure identified

Researchers Dr. Marc Therrien at the Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al, and Dr. Frank Sicheri, at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto, have discovered a new target that may be instrumental in the development of new, more effective cancer therapies.

3 Sep 2009

Colorado braces for mental health cuts, Florida nursing homes brace for Medicare cuts, and other developments

Kaiser Health News: "Three years after Massachusetts implemented a state program to provide near universal health care, officials said that a key to their success was that stakeholders from the state's health care sector and the business community had a commitment to implementing the program." Despite successes, one state official said cost containment remains a challenge (Marcy, 9/1).

3 Sep 2009

Hope for limiting skin toxicity of cancer drug users

There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson.

2 Sep 2009

Research on Ewing's sarcoma could lead to drugs for patients who do not respond to chemotherapy

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults. Their research shows that patients with poor outcomes have tumors with high levels of a protein known as GSTM4, which may suppress the effects of chemotherapy.

2 Sep 2009

Patient perception of physician disclosure key to gaining trust

When reporting medical errors, patients' perceptions of their physicians' disclosure may be key to gaining their trust, according to researchers from the Johns Hopkins Bloomberg School of Public Health. However, a positive perception of the disclosure has little effect on the lawsuit risk a physician faces.

2 Sep 2009

Vitro Diagnostics develops technology and products for cell-based cancer therapy

Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced advances in its adult stem cell products and technology with application to cell-based therapy of cancer. With the passing of Senator Edward Kennedy from brain cancer, we are reminded of such aggressive cancers without effective treatment.

2 Sep 2009

Heidelberg neuropathologists detect astrocytomas that can deactivate the "death receptor"

Malignant brain tumors often fail to respond to promising new medication. Researchers in Heidelberg have discovered a mechanism and a tumor marker for the development of this resistance. A "death receptor" can possibly provide information as to how great the chances of success are for chemotherapy. At the same time, it offers a new approach for promising brain tumor therapy.

2 Sep 2009

Chemotherapy News and Research

Latest Chemotherapy News and Research

OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor

Oncotype DX multigene expression test for breast cancer patients

NCI renews SPORE grant for the diagnosis and treatment of ovarian cancer

Endo Pharmaceuticals launches VALSTAR for treating recurrent carcinoma in situ bladder tumors

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

First-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Delcath Systems begins operations facility in Queensbury, New York

IsoFlow Infusion catheter allows physicians to increase drug concentrations at targeted sites

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

GDC-0449 inhibits the Hedgehog signaling pathway

Research reveals that 21% of death claims are rejected by California's largest private insurers

Yale University awarded $36 million ARRA funds for over 100 research projects

Avastin increases survival rates in recurrent glioblastoma affected patients

New target for cancer cure identified

Colorado braces for mental health cuts, Florida nursing homes brace for Medicare cuts, and other developments

Hope for limiting skin toxicity of cancer drug users

Research on Ewing's sarcoma could lead to drugs for patients who do not respond to chemotherapy

Patient perception of physician disclosure key to gaining trust

Vitro Diagnostics develops technology and products for cell-based cancer therapy

Heidelberg neuropathologists detect astrocytomas that can deactivate the "death receptor"

Cancer Research eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in